You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
江蘇吳中(600200.SH):卡絡磺鈉片首家通過仿製藥一致性評價
格隆匯 07-18 15:38

格隆匯7月18日丨江蘇吳中(600200.SH)公佈,公司全資子公司江蘇吳中醫藥集團有限公司下屬分支機構江蘇吳中醫藥集團有限公司蘇州製藥廠(稱“蘇州製藥廠”)收到了國家藥品監督管理局核准簽發的關於“卡絡磺鈉片”(稱“該藥品”或“本品”)的《藥品補充申請批准通知書》,該藥品通過仿製藥質量和療效一致性評價。

卡絡磺鈉是新一代腎上腺素腙衍生物止血藥,可增加毛細血管對損傷的抵抗力或使毛細血管通透性降低,增進毛細血管斷裂端的回縮作用,穩定毛細血管及周圍組織中的酸性粘多糖,顯著縮短出血時間,不影響凝血/纖溶系統,是毛細血管損傷導致出血的有效止血藥。在臨牀上卡絡磺鈉主要用於泌尿系統、上消化道、呼吸道和婦產科疾病出血,對泌尿系統出血療效較為顯著,亦可用於外傷和手術出血。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account